Meet The Professor Management of Chronic Lymphocytic Leukemia

Steven Coutre, MD

Professor of Medicine (Hematology) Stanford University School of Medicine Stanford, California



Commercial Support

These activities are supported by educational grants from AbbVie Inc and AstraZeneca Pharmaceuticals LP.



Dr Love — Disclosures

Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.



Research To Practice CME Planning Committee Members, Staff and Reviewers

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.




Dr Coutre — Disclosures

Advisory Committee	AbbVie Inc, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company
Consulting Agreements	AbbVie Inc, Adaptive Biotechnologies Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company, Syros Pharmaceuticals Inc
Contracted Research	AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Gilead Sciences Inc, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company
Data and Safety Monitoring Board/Committee	Acerta Pharma — A member of the AstraZeneca Group, BeiGene Ltd




We Encourage Clinicians in Practice to Submit Questions



Feel free to submit questions now before the program begins and throughout the program.



Familiarizing Yourself with the Zoom Interface How to answer poll questions



When a poll question pops up, click your answer choice from the available options. Results will be shown after everyone has answered.



Thank you for joining us!

CME and MOC credit information will be emailed to each participant within 5 business days.



ONCOLOGY TODAY WITH DR NEIL LOVE

Front-Line Treatment of Chronic Lymphocytic Leukemia




DR STEVEN COUTRE STANFORD UNIVERSITY SCHOOL OF MEDICINE









Dr Steven Coutre Front-Line Treatment Oncology Today with Dr Neil Love —

(15)

Dissecting the Decision: Clinical and Nursing Investigators Provide Practical Perspectives on Key Issues in Cancer Care Part 1 — Acute Myeloid Leukemia

> Tuesday, March 16, 2021 5:00 PM – 6:00 PM ET

Faculty Rhonda Hewitt, MSN, ANP, AOCNP Mark Levis, MD, PhD



Meet The Professor Optimizing the Selection and Sequencing of Therapy for Patients with Advanced Gastrointestinal Cancers

> Wednesday, March 17, 2021 5:00 PM – 6:00 PM ET

> > Faculty Alan P Venook, MD



Dissecting the Decision: Clinical and Nursing Investigators Provide Practical Perspectives on Key Issues in Cancer Care Part 2 — HER2-Positive Breast Cancer

> Thursday, March 18, 2021 5:00 PM – 6:00 PM ET

Faculty Jamie Carroll, APRN, MSN, CNP Sara Hurvitz, MD



Cases from the Community: Investigators Discuss the Role of PARP Inhibition in the Care of Actual Patients with Ovarian Cancer

> Saturday, March 20, 2021 4:00 PM – 5:00 PM ET

Faculty

Susana Banerjee, MBBS, MA, PhD Richard T Penson, MD, MRCP Shannon N Westin, MD, MPH



Meet The Professor Optimizing the Selection and Sequencing of Therapy for Patients with Renal Cell Carcinoma

Thursday, March 25, 2021 5:00 PM – 6:00 PM ET

> Faculty Robert J Motzer, MD



Meet The Professor Management of Chronic Lymphocytic Leukemia

Monday, March 29, 2021 5:00 PM – 6:00 PM ET

Faculty Philip A Thompson, MB, BS



Meet The Professor Management of Chronic Lymphocytic Leukemia

Steven Coutre, MD

Professor of Medicine (Hematology) Stanford University School of Medicine Stanford, California



Meet The Professor Program Participating Faculty



John N Allan, MD Assistant Professor of Medicine Weill Cornell Medicine New York, New York



Ian W Flinn, MD, PhD Director of Lymphoma Research Program Sarah Cannon Research Institute Tennessee Oncology Nashville, Tennessee



Steven Coutre, MD Professor of Medicine (Hematology) Stanford University School of Medicine Stanford, California



Prof John G Gribben, MD, DSc, FMedSci Chair of Medical Oncology Barts Cancer Institute Queen Mary University of London Charterhouse Square London, United Kingdom



Matthew S Davids, MD, MMSc Associate Professor of Medicine Harvard Medical School Director of Clinical Research Division of Lymphoma Dana-Farber Cancer Institute Boston, Massachusetts



Brian T Hill, MD, PhD Director, Lymphoid Malignancy Program Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio



Meet The Professor Program Participating Faculty




Nitin Jain, MD Associate Professor of Medicine Department of Leukemia The University of Texas MD Anderson Cancer Center Houston, Texas



John M Pagel, MD, PhD Chief of Hematologic Malignancies Center for Blood Disorders and Stem Cell Transplantation Swedish Cancer Institute Seattle, Washington



Brad S Kahl, MD Professor of Medicine Washington University School of Medicine Director, Lymphoma Program Siteman Cancer Center St Louis, Missouri



Kerry Rogers, MD Assistant Professor in the Division of Hematology The Ohio State University Columbus, Ohio



Anthony R Mato, MD, MSCE Associate Attending Director, Chronic Lymphocytic Leukemia Program Memorial Sloan Kettering Cancer Center New York, New York



Jeff Sharman, MD Willamette Valley Cancer Institute and Research Center Medical Director of Hematology Research US Oncology Eugene, Oregon



Meet The Professor Program Participating Faculty



Tanya Siddiqi, MD Associate Professor Director, Chronic Lymphocytic Leukemia Program Department of Hematology and Hematopoietic Cell Transplantation City of Hope National Medical Center Duarte, California



William G Wierda, MD, PhD DB Lane Cancer Research Distinguished Professor Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, Texas




Mitchell R Smith, MD, PhD Professor of Medicine Associate Center Director for Clinical Investigations Director, Division of Hematology and Oncology GW Cancer Center Washington, DC



Jennifer Woyach, MD Professor Division of Hematology Department of Internal Medicine The Ohio State University Comprehensive Cancer Center Columbus, Ohio




We Encourage Clinicians in Practice to Submit Questions



Feel free to submit questions now before the program begins and throughout the program.



Familiarizing Yourself with the Zoom Interface How to answer poll questions



When a poll question pops up, click your answer choice from the available options. Results will be shown after everyone has answered.



ONCOLOGY TODAY WITH DR NEIL LOVE

Front-Line Treatment of Chronic Lymphocytic Leukemia




DR STEVEN COUTRE STANFORD UNIVERSITY SCHOOL OF MEDICINE









Dr Steven Coutre Front-Line Treatment Oncology Today with Dr Neil Love —

(15)

Dissecting the Decision: Clinical and Nursing Investigators Provide Practical Perspectives on Key Issues in Cancer Care Part 1 — Acute Myeloid Leukemia

> Tuesday, March 16, 2021 5:00 PM – 6:00 PM ET

Faculty Rhonda Hewitt, MSN, ANP, AOCNP Mark Levis, MD, PhD



Meet The Professor Optimizing the Selection and Sequencing of Therapy for Patients with Advanced Gastrointestinal Cancers

> Wednesday, March 17, 2021 5:00 PM – 6:00 PM ET

> > Faculty Alan P Venook, MD



Dissecting the Decision: Clinical and Nursing Investigators Provide Practical Perspectives on Key Issues in Cancer Care Part 2 — HER2-Positive Breast Cancer

> Thursday, March 18, 2021 5:00 PM – 6:00 PM ET

Faculty Jamie Carroll, APRN, MSN, CNP Sara Hurvitz, MD



Cases from the Community: Investigators Discuss the Role of PARP Inhibition in the Care of Actual Patients with Ovarian Cancer

> Saturday, March 20, 2021 4:00 PM – 5:00 PM ET

Faculty

Susana Banerjee, MBBS, MA, PhD Richard T Penson, MD, MRCP Shannon N Westin, MD, MPH



Meet The Professor Optimizing the Selection and Sequencing of Therapy for Patients with Renal Cell Carcinoma

Thursday, March 25, 2021 5:00 PM – 6:00 PM ET

> Faculty Robert J Motzer, MD



Meet The Professor Management of Chronic Lymphocytic Leukemia

Monday, March 29, 2021 5:00 PM – 6:00 PM ET

Faculty Philip A Thompson, MB, BS



Meet The Professor Management of Chronic Lymphocytic Leukemia

Steven Coutre, MD

Professor of Medicine (Hematology) Stanford University School of Medicine Stanford, California





Spencer Henick Bachow, MD Hematologist/Oncologist at Lynn Cancer Institute Affiliate Assistant Professor of Medicine at FAU Schmidt College of Medicine Boca Raton, Florida



Maria Regina Flores, MD Physician Partner for Florida Cancer Specialists and Research Institute Orlando, Florida



Mamta Choksi, MD Florida Cancer Specialists and Research Institute New Port Richey, Florida



Ranju Gupta, MD Attending Physician Co-Director, Cardio-Oncology Program LVPG Hematology Oncology Associates Lehigh Valley Health Network Bethlehem, Pennsylvania



Justin Peter Favaro, MD, PhD Oncology Specialists of Charlotte Charlotte, North Carolina



Lyle Feinstein, MD Attending Physician, Malignant Hematology and Bone Marrow Transplant Miami Cancer Institute Miami, Florida



Shachar Peles, MD Florida Cancer Specialists and Research Institute Atlantis, Florida



Meet The Professor with Dr Coutre

MODULE 1: Cases from Drs Favaro, Flores and Feinstein

- Dr Favaro: A 69-year-old physician with CLL who received rituximab/venetoclax
- Dr Flores: A very active 75-year-old man with asymptomatic CLL and a WBC count of 188k
- Dr Feinstein: A 75-year-old man with CLL who experiences ibrutinib-related arthralgias

MODULE 2: Beyond the Guidelines – Part 1

MODULE 3: Cases from Drs Gupta and Peles

- Dr Gupta: An 80-year-old man who is receiving apixaban for DVT/PE and develops CLL that requires treatment
- Dr Peles: A 79-year-old woman with CLL who experiences venetoclax-related cytopenias

MODULE 4: Beyond the Guidelines – Part 2

MODULE 5: Cases from Drs Choksi and Bachow

- Dr Choksi: An 87-year-old man with CLL who receives obinutuzumab/venetoclax
- Dr Bachow: A 55-year-old woman with relapsed CLL and a BRAF V600E mutation

MODULE 6: Key Recent Data Sets



Meet The Professor with Dr Coutre

MODULE 1: Cases from Drs Favaro, Flores and Feinstein

- Dr Favaro: A 69-year-old physician with CLL who received rituximab/venetoclax
- Dr Flores: A very active 75-year-old man with asymptomatic CLL and a WBC count of 188k
- Dr Feinstein: A 75-year-old man with CLL who experiences ibrutinib-related arthralgias

MODULE 2: Beyond the Guidelines – Part 1

MODULE 3: Cases from Drs Gupta and Peles

- Dr Gupta: An 80-year-old man who is receiving apixaban for DVT/PE and develops CLL that requires treatment
- Dr Peles: A 79-year-old woman with CLL who experiences venetoclax-related cytopenias

MODULE 4: Beyond the Guidelines – Part 2

MODULE 5: Cases from Drs Choksi and Bachow

- Dr Choksi: An 87-year-old man with CLL who receives obinutuzumab/venetoclax
- Dr Bachow: A 55-year-old woman with relapsed CLL and a BRAF V600E mutation

MODULE 6: Key Recent Data Sets



Case Presentation – Dr Favaro: A 69-year-old physician with CLL who received rituximab/venetoclax

- Presents with extensive LAD and del(13) CLL
- Rituximab/cyclophosphamide/vincristine
- Develops acquired von Willebrand's disease
 - Treated with IVIG monthly to keep factor VIII levels in normal range
- Two years later: Small bowel obstruction secondary to mesenteric adenopathy
- Rituximab/venetoclax, with complete resolution of LAD
 - After 2 years, flow cytometry: 0.02% abnormal B-cell population consistent with residual CLL
 - Continues venetoclax 200 mg daily, IVIG monthly

Questions

- After 2 years on venetoclax, with the flow cytometry still being positive, would you continue venetoclax therapy? What is the best way to measure minimal residual disease in patients with CLL?
- In our patients with CLL does rituximab influence the efficacy of any vaccine, including the COVID-19 vaccine?



Dr Justin Favaro



Case Presentation – Dr Flores: A very active 75-year-old man with asymptomatic CLL and a WBC count of 188k



Dr Maria Flores

- PMH: HTN, hyperlipidemia but plays tennis daily
- 6/2017: Diagnosed with Stage I CLL
 - WBC 14k, Hgb 15, PLT 212k
- 8/2020: WBC rising to 108.6k; Diagnosed with B12 deficiency anemia, Hgb 13.9, PLT 168
 - B12 injections
- Currently, WBC 188k, Hgb 13, PLT 158 and continues to feel well
- IGHV borderline mutated, Deletion 13q14, Deletion 11q
- Patient feels great (asymptomatic) and is concerned about cost of care and insurance coverage

Questions

- Patient questions whether he needs treatment now?
- Is there an absolute WBC that will trigger you to treat? If you did decide to treat, what would you recommend?



Case Presentation – Dr Feinstein: A 75-year-old man with CLL who experiences ibrutinib-related arthralgias

- Referred by PCP for leukocytosis, anemia, fatigue; No B symptoms
 - WBC: 32.5k; ALC: 29.9k, Hgb: 9.7, PLT: 101k, LDH: 210
 - Peripheral flow cytometry: CLL, IGHV mutated
 - BMB: CLL, 80% cellularity, FISH: 13q-
 - CT/PET: Enlarged lymph nodes (none > 3 m) above and below diaphragm, Spleen: 16.4 cm
- Patient desires oral monotherapy
- Ibrutinib ongoing, tolerating remarkably well
 - Initial rise in lymphocytes, decrease in WBCs, CBC normalized
 - Arthralgias managed with NSAIDs

Questions

- How do you manage ibrutinib-associated arthralgias?
- How do you choose between ongoing therapy with either ibrutinib or acalabrutinib versus fixed-duration therapy with venetoclax/obinutuzumab?



Dr Lyle Feinstein



Meet The Professor with Dr Coutre

MODULE 1: Cases from Drs Favaro, Flores and Feinstein

- Dr Favaro: A 69-year-old physician with CLL who received rituximab/venetoclax
- Dr Flores: A very active 75-year-old man with asymptomatic CLL and a WBC count of 188k
- Dr Feinstein: A 75-year-old man with CLL who experiences ibrutinib-related arthralgias

MODULE 2: Beyond the Guidelines – Part 1

MODULE 3: Cases from Drs Gupta and Peles

- Dr Gupta: An 80-year-old man who is receiving apixaban for DVT/PE and develops CLL that requires treatment
- Dr Peles: A 79-year-old woman with CLL who experiences venetoclax-related cytopenias

MODULE 4: Beyond the Guidelines – Part 2

MODULE 5: Cases from Drs Choksi and Bachow

- Dr Choksi: An 87-year-old man with CLL who receives obinutuzumab/venetoclax
- Dr Bachow: A 55-year-old woman with relapsed CLL and a BRAF V600E mutation

MODULE 6: Key Recent Data Sets



What is your usual preferred initial regimen for a <u>60-year-old</u> patient with CLL with <u>IGHV mutation</u> but no del(17p) or TP53 mutation who requires treatment?

- 1. FCR (fludarabine/cyclosphosphamide/rituximab)
- 2. Ibrutinib
- 3. Ibrutinib + rituximab
- 4. Ibrutinib + obinutuzumab
- 5. Acalabrutinib
- 6. Acalabrutinib + obinutuzumab
- 7. Venetoclax + obinutuzumab
- 8. Other



What is your usual preferred initial regimen for a <u>60-year-old</u> patient with CLL with <u>IGHV mutation</u> but no del(17p) or TP53 mutation who requires treatment?

Dr Davids	Venetoclax + obinutuzumab	Dr Mato	FCR
Dr Flinn	Venetoclax + obinutuzumab	Dr Pagel	Acalabrutinib
Dr Hill	Venetoclax + obinutuzumab OR BR	Dr Rogers	Ibrutinib or FCR
Dr Jain	Venetoclax + obinutuzumab	Dr Siddiqi	Venetoclax + obinutuzumab

FCR = fludarabine/cyclosphosphamide/rituximab; BR = bendamustine/rituximab



What is your usual preferred initial regimen for a <u>75-year-old</u> patient with CLL with <u>IGHV mutation</u> but no del(17p) or TP53 mutation who requires treatment?

Dr Davids	Venetoclax + obinutuzumab	Dr Mato	Acalabrutinib
Dr Flinn	Acalabrutinib	Dr Pagel	Acalabrutinib
Dr Hill	Obinutuzumab	Dr Rogers	Acalabrutinib or venetoclax + obinutuzumab
Dr Jain	Venetoclax + obinutuzumab	Dr Siddiqi	Acalabrutinib + obinutuzumab



What is your usual preferred initial regimen for a <u>60-year-old</u> patient with CLL with <u>unmutated IGHV</u> and no del(17p) or TP53 mutation who requires treatment?

- 1. FCR
- 2. Ibrutinib
- 3. Ibrutinib + rituximab
- 4. Ibrutinib + obinutuzumab
- 5. Acalabrutinib
- 6. Acalabrutinib + obinutuzumab
- 7. Venetoclax + obinutuzumab
- 8. Other



What is your usual preferred initial regimen for a <u>60-year-old</u> patient with CLL with <u>unmutated IGHV</u> and no del(17p) or TP53 mutation who requires treatment?

Dr Davids	Venetoclax + obinutuzumab	Dr Mato	Venetoclax + obinutuzumab	
Dr Flinn	Venetoclax + obinutuzumab	Dr Pagel	Acalabrutinib	
Dr Hill	Venetoclax + obinutuzumab	Dr Rogers	Acalabrutinib or venetoclax + obinutuzumab	
Dr Jain	Venetoclax + obinutuzumab	Dr Siddiqi	Venetoclax + obinutuzumab	



What would be your most likely approach for a patient with newly diagnosed CLL to whom you administer up-front venetoclax/obinutuzumab who has <u>detectable</u> minimal residual disease (MRD) after 1 year of treatment?

- 1. Continue treatment
- 2. Discontinue treatment




What would be your most likely approach for a patient with newly diagnosed CLL to whom you administer up-front venetoclax/obinutuzumab who has <u>detectable</u> minimal residual disease (MRD) after 1 year of treatment?

Dr Davids	Discontinue treatment	Dr Mato	Continue treatment
Dr Flinn	Discontinue treatment	Dr Pagel	Continue treatment
Dr Hill	Discontinue treatment	Dr Rogers	Discontinue treatment
Dr Jain	Continue treatment	Dr Siddiqi	Continue treatment



What is your usual preferred initial regimen for a <u>60-year-old</u> patient with <u>del(17p)</u> CLL who requires treatment?





Meet The Professor with Dr Coutre

MODULE 1: Cases from Drs Favaro, Flores and Feinstein

- Dr Favaro: A 69-year-old physician with CLL who received rituximab/venetoclax
- Dr Flores: A very active 75-year-old man with asymptomatic CLL and a WBC count of 188k
- Dr Feinstein: A 75-year-old man with CLL who experiences ibrutinib-related arthralgias

MODULE 2: Beyond the Guidelines – Part 1

MODULE 3: Cases from Drs Gupta and Peles

- Dr Gupta: An 80-year-old man who is receiving apixaban for DVT/PE and develops CLL that requires treatment
- Dr Peles: A 79-year-old woman with CLL who experiences venetoclax-related cytopenias

MODULE 4: Beyond the Guidelines – Part 2

MODULE 5: Cases from Drs Choksi and Bachow

- Dr Choksi: An 87-year-old man with CLL who receives obinutuzumab/venetoclax
- Dr Bachow: A 55-year-old woman with relapsed CLL and a BRAF V600E mutation

MODULE 6: Key Recent Data Sets



Case Presentation – Dr Gupta: An 80-year-old man who is receiving apixaban for DVT/PE and develops CLL that requires treatment

- PMH: HTN, DVT/PE on apixaban since 2019
- 2018: Diagnosed with CLL, asymptomatic, 13q14 deletion
- Observation \rightarrow Anemia, fatigue, mild adenopathy

Questions

- What is the optimal first-line treatment for an elderly patient with a good performance status on anticoagulation? Would you recommend a BTK inhibitor, and if so, which one ibrutinib or acalabrutinib?
- Should we be using venetoclax and obinutuzumab in all of these patients?
- Is there any role for rituximab with bendamustine for 4 to 6 cycles in first-line treatment?



Dr Ranju Gupta



Case Presentation – Dr Peles: A 79-year-old woman with CLL who experiences venetoclax-related cytopenias

- PMH: Heart disease s/p CABG 2-3 months prior to CLL diagnosis
- 1/2020: Diagnosed with CLL, trisomy 12, IGHV mutated
- Obinutuzumab/venetoclax
 - Dose delays and reductions of venetoclax to 200 mg due to persistent neutropenia and thrombocytopenia
 - Repeat bone marrow due to concerns she may not be responding
 - 7/2020 FLOW: CD5 positive/CD3 23+ B cells <0.1% of cells Consistent with MRD</p>

Questions

- What's your experience with cytopenias with obinutuzumab/venetoclax, and how do you usually manage them? Do you use growth factors? Do you dose reduce? Do you discontinue one or the other agent? Do you feel one or the other agent is a more important part of this regimen?
- How do I incorporate MRD testing into my day-to-day clinical practice in CLL?



Dr Shachar Peles



Meet The Professor with Dr Coutre

MODULE 1: Cases from Drs Favaro, Flores and Feinstein

- Dr Favaro: A 69-year-old physician with CLL who received rituximab/venetoclax
- Dr Flores: A very active 75-year-old man with asymptomatic CLL and a WBC count of 188k
- Dr Feinstein: A 75-year-old man with CLL who experiences ibrutinib-related arthralgias

MODULE 2: Beyond the Guidelines – Part 1

MODULE 3: Cases from Drs Gupta and Peles

- Dr Gupta: An 80-year-old man who is receiving apixaban for DVT/PE and develops CLL that requires treatment
- Dr Peles: A 79-year-old woman with CLL who experiences venetoclax-related cytopenias

MODULE 4: Beyond the Guidelines – Part 2

MODULE 5: Cases from Drs Choksi and Bachow

- Dr Choksi: An 87-year-old man with CLL who receives obinutuzumab/venetoclax
- Dr Bachow: A 55-year-old woman with relapsed CLL and a BRAF V600E mutation

MODULE 6: Key Recent Data Sets




Which second-line systemic therapy would you recommend for a 60-year-old patient with CLL with no IGHV mutation and no del(17p) or TP53 mutation who responds to <u>ibrutinib</u> and then experiences disease progression 3 years later?

- 1. Acalabrutinib
- 2. Acalabrutinib + obinutuzumab
- 3. Venetoclax
- 4. Venetoclax + rituximab
- 5. Venetoclax + obinutuzumab
- 6. Idelalisib
- 7. Duvelisib
- 8. Other



Which second-line systemic therapy would you recommend for a 60-year-old patient with CLL with unmutated IGHV and no del(17p) or TP53 mutation who responds to <u>ibrutinib</u> and then experiences disease progression 3 years later?





Which second-line systemic therapy would you recommend for a 60-yearold patient with CLL with no IGHV mutation and no del(17p) or TP53 mutation who responds to <u>venetoclax/obinutuzumab</u> and then experiences disease progression 3 years later?

- 1. Ibrutinib
- 2. Ibrutinib + rituximab
- 3. Ibrutinib + obinutuzumab
- 4. Acalabrutinib
- 5. Acalabrutinib + obinutuzumab
- 6. Idelalisib
- 7. Duvelisib
- 8. Other



Which second-line systemic therapy would you recommend for a 60-year-old patient with CLL with unmutated IGHV and no del(17p) or TP53 mutation who responds to <u>venetoclax/obinutuzumab</u> and then experiences disease progression 3 years later?

Dr Davids	Venetoclax + obinutuzumab	Dr Mato	Venetoclax + rituximab	
Dr Flinn	Acalabrutinib	Dr Pagel	Acalabrutinib	
Dr Hill	Acalabrutinib	Dr Rogers	Ibrutinib	
Dr Jain	Acalabrutinib	Dr Siddiqi	Acalabrutinib + obinutuzumab	



A <u>60-year-old</u> patient with CLL, an absolute lymphocyte count of <u>80,000</u> and several involved lymph nodes that are <u>larger than 5 centimeters</u> is about to receive venetoclax. What preemptive measures, if any, would you take to address tumor lysis syndrome prior to the initiation of therapy?

Dr Davids	Admit to hospital	Dr Mato	Admit to hospital	
Dr Flinn	Debulk with obinutuzumab	Dr Pagel	Admit to hospital	
Dr Hill	Admit to hospital	Dr Rogers	Admit to hospital	
Dr Jain	Admit to hospital	Dr Siddiqi	Admit to hospital	



Meet The Professor with Dr Coutre

MODULE 1: Cases from Drs Favaro, Flores and Feinstein

- Dr Favaro: A 69-year-old physician with CLL who received rituximab/venetoclax
- Dr Flores: A very active 75-year-old man with asymptomatic CLL and a WBC count of 188k
- Dr Feinstein: A 75-year-old man with CLL who experiences ibrutinib-related arthralgias

MODULE 2: Beyond the Guidelines – Part 1

MODULE 3: Cases from Drs Gupta and Peles

- Dr Gupta: An 80-year-old man who is receiving apixaban for DVT/PE and develops CLL that requires treatment
- Dr Peles: A 79-year-old woman with CLL who experiences venetoclax-related cytopenias

MODULE 4: Beyond the Guidelines – Part 2

MODULE 5: Cases from Drs Choksi and Bachow

- Dr Choksi: An 87-year-old man with CLL who receives obinutuzumab/venetoclax
- Dr Bachow: A 55-year-old woman with relapsed CLL and a BRAF V600E mutation

MODULE 6: Key Recent Data Sets



Case Presentation – Dr Choksi: An 87-year-old man with CLL who receives obinutuzumab/venetoclax

- PMH: HTN, diabetes, CAD, shingles
- 8/2020: Evaluated for lymphocytosis and thrombocytopenia
 - PLT: 90,000, Absolute lymphocytes: 6,000
- Workup: CD38-negative CLL, trisomy 12, IGHV-unmutated; Mild LAD in neck, chest, abdomen and pelvis with more extensive LAD in mediastinum and bilateral axillary region
- 9/2020: Initiates obinutuzumab/venetoclax regimen
 - − Allopurinol \rightarrow Obinutuzumab 100 mg C1D1, 900 mg C1D2
 - Thrombocytopenia with PLT: 14,000 \rightarrow Platelet transfusion \rightarrow PLT 40,000
 - Holding treatment for another week to re-evaluate

Question

• What are your experiences with obinutuzumab/venetoclax in older patients with CLL?



Dr Mamta Choksi



Case Presentation – Dr Bachow: A 55-year-old woman with relapsed CLL and a BRAF V600E mutation



Dr Spencer Bachow

- 9/2012: Diagnosed with CLL \rightarrow Surveillance
- 7/2013: Presents to MD Anderson, with CLL Del (13q), IGHV-unmutated \rightarrow Continues surveillance
- 7/2015: Increasing fatigue, anemia, RBC \rightarrow patient declines chemotherapy
- 7/2016: FCR x 3, Complete hematologic remission but declined further FCR due to toxicity \rightarrow Surveillance
 - WBC increased from 6.6k to 27.7k in 4 months
 - Molecular testing: BRAF V600E and KRAS mutations
- 10/2016: Ibrutiinib, with arthralgias and weight gain \rightarrow Switched to 2 tablets daily
 - 2/2019: Ibrutinib discontinued due to severe arthralgias, fatigue \rightarrow Surveillance
- 10/2020: WBC increased to 157.0k, with more prominent axIllary, cervical and supraclavicular LAD, fatigue
- Acalabrutinib

Question

• Have you ever seen BRAF V600E mutations in CLL? Could she have more of a hairy cell leukemia-like B-cell lymphoproliferative disorder? Have you ever used BRAF-targeted therapy in CLL off protocol?



Meet The Professor with Dr Coutre

MODULE 1: Cases from Drs Favaro, Flores and Feinstein

- Dr Favaro: A 69-year-old physician with CLL who received rituximab/venetoclax
- Dr Flores: A very active 75-year-old man with asymptomatic CLL and a WBC count of 188k
- Dr Feinstein: A 75-year-old man with CLL who experiences ibrutinib-related arthralgias

MODULE 2: Beyond the Guidelines – Part 1

MODULE 3: Cases from Drs Gupta and Peles

- Dr Gupta: An 80-year-old man who is receiving apixaban for DVT/PE and develops CLL that requires treatment
- Dr Peles: A 79-year-old woman with CLL who experiences venetoclax-related cytopenias

MODULE 4: Beyond the Guidelines – Part 2

MODULE 5: Cases from Drs Choksi and Bachow

- Dr Choksi: An 87-year-old man with CLL who receives obinutuzumab/venetoclax
- Dr Bachow: A 55-year-old woman with relapsed CLL and a BRAF V600E mutation





Optimal Integration of BTK Inhibitors and Venetoclax into First-Line Treatment



The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE


Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

J.A. Woyach, A.S. Ruppert, N.A. Heerema, W. Zhao, A.M. Booth, W. Ding,
N.L. Bartlett, D.M. Brander, P.M. Barr, K.A. Rogers, S.A. Parikh, S. Coutre,
A. Hurria,* J.R. Brown, G. Lozanski, J.S. Blachly, H.G. Ozer, B. Major-Elechi,
B. Fruth, S. Nattam, R.A. Larson, H. Erba, M. Litzow, C. Owen, C. Kuzma,
J.S. Abramson, R.F. Little, S.E. Smith, R.M. Stone, S.J. Mandrekar, and J.C. Byrd

N Engl J Med 2018;379(26):2517-28.



Phase III Alliance A041202 Study Design




Primary endpoint: Progression-free survival (PFS) **Secondary endpoints:** OS, ORR, Impact of MRD on PFS and OS, Duration of response, Toxicity and Tolerability

Woyach JA et al. *N Engl J Med* 2018;379(26):2517-28. Woyach J et al. Alliance Fall Group Meeting, November 5, 2015.



Alliance A041202: Efficacy with Ibrutinib Alone or in Combination with Rituximab Compared to Bendamustine/Rituximab



Months

Alliance A041202: Grade 3 to 5 Adverse Events of Special Interest

Adverse event	Bendamustine + rituximab (N = 176)	Ibrutinib (N = 180)	lbrutinib + rituximab (N = 181)	<i>p</i> -value
Hematologic – Any Grade 3-4	61%	41%	39%	<0.001
Anemia	12%	12%	6%	0.09
Decreased neutrophil count	40%	15%	21%	<0.001
Decreased platelet count	15%	7%	5%	0.008
Nonhematologic – Any Grade 3-5	63%	74%	74%	0.04
Bleeding	0	2%	3%	0.46
Infections	15%	20%	21%	0.62
Febrile neutropenia	7%	2%	1%	<0.001
Atrial fibrillation	3%	9%	6%	0.05
Hypertension	15%	29%	34%	<0.001




Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-Up from the E1912 Trial

Shanafelt TD et al. ASH 2019;Abstract 33.



Phase III ECOG-ACRIN E1912 Study Design




Primary endpoint: PFS **Secondary endpoints:** OS, ORR, Toxicity and Tolerability

ECOG-ACRIN E1912 Physician Fact Sheet, version 01/15/16; www.clinicaltrials.gov (NCT02048813); Shanafelt TD et al. ASH 2018;Abstract LBA-4.



ECOG-ACRIN E1912 Extended Follow-Up: Up-Front IR Compared to FCR for Younger Patients with CLL



- Grade ≥3 treatment-related AEs were reported in 70% of patients receiving IR and 80% of patients receiving FCR (odds ratio = 0.56; *p* = 0.013).
- Among the 95 patients who discontinued ibrutinib, the most common cause was AE or complication.



Shanafelt TD et al. ASH 2019; Abstract 33.




Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

Jeff P Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, John M Pagel, Ian W Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Maria Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutre, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, Jennifer A Woyach, Gilles Salles, William G Wierda, Raquel Izumi, Veerendra Munugalavadla, Priti Patel, Min Hui Wang, Sofia Wong, John C Byrd

Lancet 2020;395(10232):1278-91.



ELEVATE-TN Phase III Trial Schema




Primary endpoint: Progression-free survival



www.clinicaltrials.gov (NCT02475681). Accessed August 2020.







Sharman JP et al. *Lancet* 2020;395:1278-91.

ELEVATE-TN: Select Safety Parameters

	Acalabrutinib/obinutuzumab (n = 178)		Acalabrutinib (n = 179)		Obinutuzumab/chlorambucil (n = 169)	
	Grade 1-2	Grade ≥3	Grade 1-2	Grade ≥3	Grade 1-2	Grade ≥3
Any AE	26%	70%	45%	50%	29%	70%
Serious AE	6%	33%	2%	30%	2%	20%
AE leading to drug discontinuation	11%		9%		14%	
Neutropenia	2%	30%	1%	10%	4%	41%
Grade ≥3 infections						
Infusion-related reactions	11%	2%	0	0	34%	5%



Acalabrutinib Met Primary Efficacy Endpoint in Head-to-Head Trial Against Ibrutinib for Chronic Lymphocytic Leukemia Press Release — January 25, 2021

"Positive high-level results from the ELEVATE-RR Phase III trial showed acalabrutinib met the primary endpoint demonstrating non-inferior progression-free survival (PFS) for adults with previously treated, high-risk chronic lymphocytic leukemia (CLL) compared to ibrutinib.

The trial also met a key secondary endpoint for safety, showing patients treated with acalabrutinib had statistically significantly lower incidence of atrial fibrillation compared to patients treated with ibrutinib. Atrial fibrillation is an irregular heart rate that can increase the risk of stroke, heart failure and other heart-related complications. Further hierarchical testing revealed no difference for Grade 3 or higher infections or Richter's transformation. There was a descriptive trend for numerically favorable overall survival. Overall, the safety and tolerability of acalabrutinib were consistent with the profile seen in the broader acalabrutinib clinical development program.

ELEVATE-RR is the first Phase III trial to compare two Bruton's tyrosine kinase (BTK) inhibitors in patients with CLL, the most common type of leukemia in adults."




Ibrutinib (Ibr) plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results from the MRD Cohort of the Phase 2 CAPTIVATE Study Trial

Wierda WG et al. ASH 2020;Abstract 123.



CAPTIVATE Phase II Trial of First-Line Ibrutinib with Venetoclax for CLL: 1-Year DFS Results from the MRD Cohort



^aThe 3 DFS events in placebo arm were disease progression in 2 patients and MRD relapse in 1 patient.

30 month PFS Rate:

Confirmed uMRD:

- 95.3% placebo
- 100% ibrutinib

Without confirmed uMRD:


- 95.2% ibrutinib
- 96.7% ibr/ven

AEs were primarily Grade 1/2 and mostly occurred in early cycles of Ibr + Ven, with modest differences by randomized treatment arm.



Wierda WG et al. ASH 2020; Abstract 123.

Phase III EA9161 Schema



Clinicaltrials.gov/ct2/show/NCT03701282?term=EA9161&draw=2&rank=1, Accessed March 1, 2021






Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

Othman Al-Sawaf, Can Zhang, Maneesh Tandon, Arijit Sinha, Anna-Maria Fink, Sandra Robrecht, Olga Samoylova, Anna M Liberati, Javier Pinilla-Ibarz, Stephen Opat, Liliya Sivcheva, Katell Le Dû, Laura M Fogliatto, Carsten U Niemann, Robert Weinkove, Sue Robinson, Thomas J Kipps, Eugen Tausch, William Schary, Matthias Ritgen, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Barbara Eichhorst, Stephan Stilgenbauer, Michael Hallek*, Kirsten Fischer*

Lancet Oncol 2020;21(9):1188-200.




CLL14: PFS by IGHV and TP53 Mutation Status





CLL14: Landmark Analysis from End of Therapy PFS by MRD Group






Al-Sawaf O et al. Lancet Oncol 2020;21(9):1188-200.

Clonal Dynamics After Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial

Al-Sawaf O et al. ASH 2020;Abstract 127.



CLL14 Phase III Study Schema



Primary endpoint: Progression-free survival

- Treatment duration in both groups: 12 cycles, 28 days each
- No crossover was allowed
- Daily oral venetoclax regimen:
 - Initiated on day 22 of cycle 1, starting with a 5-week dose ramp-up (1 week each of 20, 50, 100 and 200 mg, then 400 mg daily for 1 week)
 - Thereafter continuing at 400 mg daily until completion of cycle 12


www.clinicaltrials.gov (NCT02242942). Accessed August 2020. Fischer K et al. *N Engl J Med* 2019;380(23):2225-36.



CLL14: Updated 4-Year PFS

4-YEAR FOLLOW-UP: PROGRESSION-FREE SURVIVAL

Median observation time 52.4 months



HR 0.33, 95% CI [0.25-0.45] P<0.0001



Al-Sawaf O et al. ASH 2020; Abstract 127.

Management of Relapsed/Refractory CLL




Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

Kater AP et al. ASH 2020;Abstract 125.



MURANO: 5-Year Follow-Up of Venetoclax/Rituximab (Ven/R) in R/R CLL



EOT, end of treatment; MRD, minimal residual disease; OS, overall survival; PB, peripheral blood; PD, progressive disease; pts, patients; Tx, therapy; uMRD, undetectable minimal residual disease; Ven, venetoclax.

- Median PFS for VenR: 53.6 mo
- 5 year OS rate: 82%
- Of 83 patients with uMRD at end of therapy, 38.5% remained uMRD
- 25 months was the average time from MRD conversion to requirement for therapy




Kater AP et al. ASH 2020; Abstract 125.

Efficacy of Subsequent Novel Targeted Therapies, Including Repeated Venetoclax-Rituximab (VenR), in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Previously Treated with Fixed-Duration VenR in the MURANO Study

Harrup R et al. ASH 2020;Abstract 3139.




MURANO: TTNT with VenR versus BR





Efficacy of Subsequent Novel Targeted Therapies in Patients Treated on the MURANO Trial: Conclusions





Harrup R et al. ASH 2020; Abstract 3139.

Venetoclax Re-Treatment of Chronic Lymphocytic Leukemia Patients after a Previous Venetoclax-based Regimen

Meghan C. Thompson, MD¹, John N. Allan, MD², Kavita Sail, PhD³, Beenish S. Manzoor, PhD, MPH⁴, Jeffrey J. Pu, MD, PhD⁵, Paul M. Barr, MD⁶, Callie C. Coombs, MD⁷, Stephen J. Schuster, MD⁸, Alan Skarbnik, MD⁹, Joanna M Rhodes, MD¹⁰, Jacqueline C. Barrientos, MD¹⁰, Lindsey E Roeker, MD¹, Lori A. Leslie, MD¹¹, Manali Kamdar, MD¹², Michael Y. Choi, MD¹³, Martin Simkovic, MD, PhD¹⁴, Frederick Lansigan, MD¹⁵, Brittany Jane Hale, MD¹⁵, Andrew D Zelenetz, MD, PhD¹⁶, Alison J. Moskowitz, MD¹, Kurt S. Bantilan, MPH¹, Celina J. Komari, BS¹, Andre H. Goy, MD¹, Tatyana A. Feldman, MD¹¹, Richard R. Furman, MD² and Anthony R. Mato, MD¹



Study Design and Endpoints

- Multicenter, retrospective study
- 13 centers and the CLL Collaborative Study of Real-World Evidence (CORE) database
- Eligibility:
 - CLL patients treated with Ven-based regimen (any line of therapy, Ven1)
 - Then re-treated with second Ven-based regimen (Ven2) in a later line of therapy
- Data collected by investigators at individual sites
 - Demographics, prognostic disease characteristics, tumor lysis syndrome risk and incidence, clinical response and reasons for treatment discontinuation

- Primary endpoint:
 - Investigator-assessed ORR
 - CR: complete response, PR: partial response, SD: stable disease, PD: progression of disease, iwCLL 2018
- PFS estimated by Kaplan-Maier method
- All other analyses descriptive






Conclusions


- ORR: High ORR of 72.2% for Ven re-treatment
- Heavily pretreated population: Cohort studied had median 2 prior therapies, majority R/R (88%), BTKi exposed (60%)
- Safety: TLS rare event and majority were able to tolerate 400 mg daily
- Improved outcomes with time: Patients with CR to Ven re-treatment had a longer median follow-up than PR or SD patients
 - Potential for better responses with longer time on therapy?
- Next steps: Longer follow-up and prospective validation of Ven retreatment → potential role of Ven re-treatment in sequencing algorithms




Overview of BTK Inhibitors in CLL


Irreversible








Reversible










Courtesy of Matthew S Davids, MD, MMSc

LOXO-305 is a Highly Potent and Selective Non-Covalent BTK Inhibitor

Highly selective for BTK BT CMG

Kinome selectivity

Xenograft models *In vivo* activity similarly efficacious as ibrutinib in WT; superior in C481S



- Nanomolar potency against WT & C481-mutant BTK in cell and enzyme assays^{1,2}
- >300-fold selectivity for BTK vs 370 other kinases¹
- Due to reversible binding mode, BTK inhibition not impacted by intrinsic rate of BTK turnover¹
- Favorable pharmacologic properties allow sustained BTK inhibition throughout dosing interval¹

BID, twice-daily; BTK, Bruton tyrosine kinase. Illustration reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com). ¹Brandhuber et al. Clin. Lymphoma Myeloma Leuk. 2018;18:S216. ²Mato et al. Blood. 2019:134 (Suppl 1):501.


Mato AR et al. ASH 2020; Abstract 542.

LOXO-305, a Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study

Mato AR et al. ASH 2020;Abstract 542.



BRUIN: LOXO-305 for Previously Treated CLL/SLL (Median prior therapies: 4)



* 11 efficacy-evaluable pts are not included in the waterfall plot, including 1 pt who discontinued prior to first response assessment, and 10 pts (4 pts with PR/PR-L and 6 pts with SD) with incomplete tumor lesion measurement data at the time of data cut



BRUIN: Safety

Adverse Events, at All Doses and Patients (N=323), n (%)		Tr	Treatment-Emergent AEs, (≥10%)ª				Treatment-Related AEs	
		Any Grade	Grade 1	Grade 2	Grade 3	Any Grade	Grade 3/4	
Fatigue		65 (20)	40 (12)	22 (7)	3 (1)	27 (8)	2 (<1)	
Diarrhea		55 (17)	45 (14)	10 (3)	-	28 (9)	-	
Contusion		42 (13)	37 (12)	5 (2)	-	29 (9)	-	
AEs of special interest, ^{b,c}	Bruising	53 (16)	48 (15)	5 (2)	-	37 (12)	-	
	Rash	35 (11)	30 (9)	5 (2)	-	18 (6)	-	
	Arthralgia	16 (5)	13 (4)	3 (1)	-	5 (2)	-	
	Hemorrhage	15 (5)	10 (3)	4 (1)	1 (<1) ^d	5 (2)	-	
	Hypertension	15 (5)	2 (<1)	9 (3)	4 (1)	4 (1)	-	
	AFib/Flutter	2 (<1)	-	2 (<1) ^e	-	-	-	

- No DLTs reported and MTD not reached
- 5 (1.5%) discontinued due to treatment-related AEs
- 200 mg QD selected as recommended phase 2 dose




Updated Follow-Up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients

Siddiqi T et al. ASH 2020;Abstract 546.



TRANSCEND CLL 04: Liso-cel Monotherapy Cohort



- ORR/CR = 82%/68%
- Median PFS 13 mo and DOR 50% at 12 mo
- Gr 3 CRS= 9% and NE 22% (No Grade 4/5)
- 4 of 6 progressions due to RT



Siddiqi T et al. ASH 2020; Abstract 546.

Dissecting the Decision: Clinical and Nursing Investigators Provide Practical Perspectives on Key Issues in Cancer Care Part 1 — Acute Myeloid Leukemia

> Tuesday, March 16, 2021 5:00 PM – 6:00 PM ET

Faculty Rhonda Hewitt, MSN, ANP, AOCNP Mark Levis, MD, PhD

> Moderator Neil Love, MD



Thank you for joining us!

CME and MOC credit information will be emailed to each participant within 5 business days.

